# CARISMA Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carisma-therapeutics

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.carismatx.com
- Total disclosed funding: $97M
- Latest round: Series B (Dec 12, 2020)
- Investors on record: 14

## About

Based in the US, CARISMA Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment using its proprietary CAR-M platform.CARISMA Therapeutics Inc. is dedicated to creating novel cancer therapies through its CAR-M technology. Founded in 2016, the company is headquartered in Philadelphia, US. The founders, Michael Klichinsky and Saar Gill, have backgrounds that include involvement in other biotechnology ventures. The company has successfully raised USD 30.00 mn through PIPE funding on September 21, 2022, attracting investors like AbbVie Biotech Ventures and HealthCap. This most recent funding round brought the total amount raised by the company to USD 30.00 mn.CARISMA Therapeutics offers a unique range of therapeutic products that leverage its CAR-M platform, aiming to overcome challenges in cancer treatment. These innovative therapies are designed specifically for addressing various cancer types, targeting healthcare providers and institutions seeking advanced treatment options. The company's solutions have been integrated into clinical settings, primarily within North America and Europe, where they aim to improve patient outcomes and streamline treatment processes.CARISMA Therapeutics generates revenue through strategic partnerships with healthcare providers and institutions for its therapeutic solutions. The revenue model is structured around cooperative agreements and licensing arrangements, facilitating sustained income from collaborative research and development projects. This approach enables the company to foster long-term relationships with partners while ensuring stable revenue streams from its products.Looking ahead, CARISMA Therapeutics plans to expand its product offerings with new therapies expected to be launched in the next 18 months, enhancing its CAR-M platform capabilities. The company is also targeting expansion into European markets, aiming to establish operations by the end of 2024. The recent PIPE funding of USD 30.00 mn will support these initiatives, allowing for increased research and development efforts, as well as strategic marketing to penetrate new regions effectively.

## Funding rounds

- Series B, Dec 12, 2020, $38M — Wellington Partners, HealthCap, TPG Biotech, Longview Innovation, AbbVie Ventures, 4BIO Capital Partners, Agent Capital, MRL Ventures Fund, SymBiosis LLC, Solasta Ventures, Livzon Pharmaceutical Group Inc.
- Series A, Aug 8, 2019, $6M — HealthCap, AbbVie Ventures
- Series A, Jun 27, 2018, $53M — Wellington Partners, HealthCap, TPG Biotech, Merck Global Health Innovation Fund, Longview Innovation, Grazia Equity, AbbVie Ventures, Penn Medicine, Agent Capital
- Seed, Jun 12, 2017 — HealthCap, Longview Innovation, Grazia Equity, AbbVie Ventures

## Investors

- HealthCap — Seed, Series A, Series B
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Seed, Series A, Series B
- Grazia Equity (https://capitalatlas.ai/funds/grazia-equity) — Seed, Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Seed, Series A, Series B
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series A, Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series A, Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A
- Penn Medicine — Series A
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series A, Series B
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Series B
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series B
- SymBiosis LLC — Series B
- Solasta Ventures (https://capitalatlas.ai/funds/solasta-ventures) — Series B
- Livzon Pharmaceutical Group Inc. — Series B